Sanofi announced a two-year pharma partnering agreement with Massachusetts General Hospital (MGH) aimed at furthering translational medicine research to develop new treatments for various types of hematological malignancies and solid tumors.
The project-based pharma partnering collaboration unites scientists from MGH and Sanofi, with the goal of maximizing the strengths of both academic and industry cross-organizational expertise, and will include both pre-clinical and clinical translational research to elucidate questions from proof-of-concept to tolerability, efficacy and effectiveness.
The initial pharma partnering agreement is for two years with the option to extend for a longer term at the discretion of both partners.
Financial details of this pharma partnering collaboration were not disclosed.
For further deal information visit Current Agreements (subscription required)
Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary
Related reports: Oncology Partnering Terms and Agreements
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity